Trial US-1528 is an open-label study to analyze the efficacy of an HPV therapeutic vaccine containing a DNA plasmid targeting E6, E7 and IL-12 in combination with Durvalumab, an anti-PD-L1, in recurrent or metastatic HPV associated cancers. Here, CD274 is linked to cancer.